About Boryung Pharmaceutical
Boryung Pharmaceutical is a company based in Seoul (South Korea) founded in 1963.. The company has 1,650 employees as of December 31, 2024. Boryung Pharmaceutical has completed 1 acquisition, including ViGenCell. Boryung Pharmaceutical offers products and services including Pharmaceutical Products and Investor Relations Services.
- Headquarter Seoul, South Korea
- Employees 1650 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Boryung Corporation
-
Annual Revenue
$691.63 M (USD)18.32as on Dec 31, 2024
-
Net Profit
$47.21 M (USD)73.2as on Dec 31, 2024
-
EBITDA
$76.84 M (USD)1.09as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
1650
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Boryung Pharmaceutical
Boryung Pharmaceutical is a publicly listed company on the KRX with ticker symbol 003850 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Boryung Pharmaceutical
Boryung Pharmaceutical offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Investor Relations Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Pharmaceutical drugs and related items are offered by the company in the healthcare sector.
Information on company history and missions is provided to investors through designated platforms.
Funding Insights of Boryung Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Boryung Pharmaceutical
Boryung Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ViGenCell. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
T-cell therapies for tumor treatment are developed by ViGenCell.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Boryung Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Boryung Pharmaceutical Comparisons
Competitors of Boryung Pharmaceutical
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Boryung Pharmaceutical
Frequently Asked Questions about Boryung Pharmaceutical
When was Boryung Pharmaceutical founded?
Boryung Pharmaceutical was founded in 1963.
Where is Boryung Pharmaceutical located?
Boryung Pharmaceutical is headquartered in Seoul, South Korea.
Who is the current CEO of Boryung Pharmaceutical?
Tae Choi is the current CEO of Boryung Pharmaceutical.
How many employees does Boryung Pharmaceutical have?
As of Dec 31, 2024, the latest employee count at Boryung Pharmaceutical is 1,650.
What is the annual revenue of Boryung Pharmaceutical?
Annual revenue of Boryung Pharmaceutical is $691.63M as on Dec 31, 2024.
What does Boryung Pharmaceutical do?
Boryung Pharmaceutical was established in 1963 and is headquartered in Seoul, South Korea. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) and finished formulations are produced for multiple disease categories. Development activities span various therapeutic areas, supporting drug manufacturing and distribution primarily within the Asian market. Leadership is provided by CEO Tae Choi, overseeing core research and production processes.
What products or services does Boryung Pharmaceutical offer?
Boryung Pharmaceutical offers Pharmaceutical Products and Investor Relations Services.
Is Boryung Pharmaceutical publicly traded?
Yes, Boryung Pharmaceutical is publicly traded on KRX under the ticker symbol 003850.
How many acquisitions has Boryung Pharmaceutical made?
Boryung Pharmaceutical has made 1 acquisition, including ViGenCell.
What is Boryung Pharmaceutical's ticker symbol?
The ticker symbol of Boryung Pharmaceutical is 003850 on KRX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.